Clinical Trial Update: DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update studying the immune microenvironment in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Tae Won Kim | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING